An antigen-specific chimeric autoantibody receptor (CAAR) NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells
January 2024 | New Publication
Seifert L, Riecken K et al., Kidney Int. 2024
In this pilot study, the Laboratory for Antigen-specific Disease Targeting describe the generation of CAAR natural killer (NK)-92 cells and primary human CAAR T cells expressing the immunodominant regions of the MN antigens PLA2R1 and THSD7A. We show that these cells specifically and efficiently eliminate anti–PLA2R1- and anti–THSD7A-secreting cells in vitro, demonstrating the principal feasibility of this strategy.
For further information visit:
KI - An antigen-specific chimeric autoantibody receptor (CAAR) NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells
Martinistraße 52
Campus Research N27
20246 Hamburg Germany
